Skip to main content
. 2007 Jan 29;66(10):1339–1344. doi: 10.1136/ard.2006.062760

Table 3 Numbers of infections and RR (estimated through Cox regression) for hospitalisation with infection during time on first tumour necrosis factor (TNF) antagonist treatment 1999–2003 in the Swedish Inpatient rheumatoid arthritis (RA) cohort, by time since start of TNF antagonist treatment, among 44 946 RA patients of whom 2692 patients started treatment with a first TNF antagonist.

During first TNF antagonist TNF antagonist naive RR by time since treatment start*
No. of events Crude rate per 100 No of events Year 1 Year 2 Year 3
Any infection 261 5.4 10 669 1.43 (1.18 to 1.72) 1.15 (0.88 to 1.51) 0.82 (0.62 to 1.08)
 Respiratory 111 2.2 6046 1.24 (0.92 to 1.68) 1.45 (1.00 to 2.09) 0.68 (0.44 to 1.05)
 Pneumonia 79 1.5 4704 1.11 (0.77 to 1.60) 1.31 (0.86 to 1.93) 0.59 (0.35 to 0.99)
 Gastrointestinal 24 0.5 1517 1.03 (0.58 to 1.81) 0.13 (0.02 to 0.91) 0.94 (0.45 to 1.94)
 Skin/soft tissue 21 0.4 1004 0.57 (0.21 to 1.57) 1.01 (0.48 to 2.16) 0.82 (0.39 to 1.76)
 Joint 25 0.5 652 1.26 (0.66 to 2.40) 0.17 (0.02 to 1.28) 1.42 (0.67 to 2.98)
 Septicaemia 36 0.7 1,716 1.07 (0.65 to 1.77) 0.71 (0.33 to 1.55) 0.62 (0.32 to 1.18)

*Cox model stratified for sex, year of birth, county of residence and using calendar time as time scale. Adjusted for marital status, chronic obstructive pulmonary disease, any cardiovascular disease, any pre‐treatment infection, diabetes, joint replacements in hip, knee, shoulder and ankle, respectively, total number of days spent in hospital and number of discharges listing RA. All time‐varying covariates were assessed as time‐dependent variables until 1 year before the outcome.